NUTX vs ASTH

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 29, 2026

NUTX

33.6
AI Score
VS
ASTH Wins

ASTH

55.3
AI Score

Investment Advisor Scores

NUTX

34score
Recommendation
SELL

ASTH

55score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric NUTX ASTH Winner
Revenue 165.57M 1.94B ASTH
Net Income -410.03M 34.17M ASTH
Net Margin -247.6% 1.8% ASTH
Operating Income -400.82M 62.85M ASTH
ROE -371.1% 4.1% ASTH
ROA -95.0% 1.5% ASTH
Total Assets 431.75M 2.28B ASTH
Cash 36.62M 400.79M ASTH
Debt/Equity 0.22 1.06 NUTX
Current Ratio 2.45 1.23 NUTX
Free Cash Flow 23.59M 92.93M ASTH

Relative Price Performance (Last 90 Days)

NUTX 1M: +13.7% · 3M: +12.7% ASTH 1M: -7.4% · 3M: -23.9%

Current Technical Phase

NUTX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 61

RSI (14): 61.1 · Price: $218.21

ASTH

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 46.5 · Price: $35.70

Fundamentals Snapshot

Metric NUTX ASTH
Market Cap — —
Forward P/E 7.8 9.9
Trailing P/E 8.2 43.1
Revenue (TTM) — —
Revenue Growth -0.1% 0.5%
Gross Margin 0.5% 0.1%
Operating Margin 0.6% 0.0%
EPS 25.88 0.81
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, ASTH is currently the stronger investment candidate, winning 9 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.